The effect of dietary glutamate on fibromyalgia and irritable bowel symptoms

Kathleen F. Holton, Douglas L Taren, Cynthia Thomson, Robert M. Bennett, Kim D. Jones

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Objective: To examine the effects of a challenge with monosodium glutamate (MSG) as compared to placebo on the symptoms of fibromyalgia (FM), in participants who initially experienced <30% remission of symptoms on an excitotoxin elimination diet. Methods: Fifty-seven FM patients who also had irritable bowel syndrome (IBS) were placed on a 4-week diet that excluded dietary additive excitotoxins including MSG and aspartame. Thirtyseven people completed the diet and 84% of those reported that <30% of their symptoms resolved, thus making them eligible to proceed to challenges. Subjects who improved on the diet were then randomised to a 2-week doubleblind placebo-controlled crossover challenge with MSG or placebo for 3 consecutive days each week. The primary outcome measure was total symptom score. Secondary outcome measures included visual analogue pain scales (VAS for FM and IBS), an IBS Quality of Life Questionnaire (IBS QOL) and the Fibromyalgia Impact QuestionnaireRevised (FIQR). Repeated measures ANOVA was used to analyse crossover challenge results. Results: The MSG challenge, as compared to placebo, resulted in a significant return of symptoms (total symptom score, p>0.02); a worsening of fibromyalgia severity as determined by the FIQR (p>0.03); decreased quality of life in regards to IBS symptoms (IBS QOL, p>0.05); and a non-significant trend toward worsening FM pain based on visual analogue scale (VAS, p>0.07). Conclusion: These findings suggest that dietary glutamate may be contributing to FM symptoms in some patients. Future research on the role of dietary excitotoxins in FM is warranted.

Original languageEnglish (US)
JournalClinical and Experimental Rheumatology
Volume30
Issue numberSUPPL.74
StatePublished - 2012

Fingerprint

Fibromyalgia
Glutamic Acid
Sodium Glutamate
Neurotoxins
Visual Analog Scale
Placebos
Quality of Life
Pain

Keywords

  • Adverse effects
  • Diet
  • Fibromyalgia
  • Glutamate
  • Irritable bowel syndrome

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

The effect of dietary glutamate on fibromyalgia and irritable bowel symptoms. / Holton, Kathleen F.; Taren, Douglas L; Thomson, Cynthia; Bennett, Robert M.; Jones, Kim D.

In: Clinical and Experimental Rheumatology, Vol. 30, No. SUPPL.74, 2012.

Research output: Contribution to journalArticle

@article{255c3dff2e274e6dbe54a30781059e7f,
title = "The effect of dietary glutamate on fibromyalgia and irritable bowel symptoms",
abstract = "Objective: To examine the effects of a challenge with monosodium glutamate (MSG) as compared to placebo on the symptoms of fibromyalgia (FM), in participants who initially experienced <30{\%} remission of symptoms on an excitotoxin elimination diet. Methods: Fifty-seven FM patients who also had irritable bowel syndrome (IBS) were placed on a 4-week diet that excluded dietary additive excitotoxins including MSG and aspartame. Thirtyseven people completed the diet and 84{\%} of those reported that <30{\%} of their symptoms resolved, thus making them eligible to proceed to challenges. Subjects who improved on the diet were then randomised to a 2-week doubleblind placebo-controlled crossover challenge with MSG or placebo for 3 consecutive days each week. The primary outcome measure was total symptom score. Secondary outcome measures included visual analogue pain scales (VAS for FM and IBS), an IBS Quality of Life Questionnaire (IBS QOL) and the Fibromyalgia Impact QuestionnaireRevised (FIQR). Repeated measures ANOVA was used to analyse crossover challenge results. Results: The MSG challenge, as compared to placebo, resulted in a significant return of symptoms (total symptom score, p>0.02); a worsening of fibromyalgia severity as determined by the FIQR (p>0.03); decreased quality of life in regards to IBS symptoms (IBS QOL, p>0.05); and a non-significant trend toward worsening FM pain based on visual analogue scale (VAS, p>0.07). Conclusion: These findings suggest that dietary glutamate may be contributing to FM symptoms in some patients. Future research on the role of dietary excitotoxins in FM is warranted.",
keywords = "Adverse effects, Diet, Fibromyalgia, Glutamate, Irritable bowel syndrome",
author = "Holton, {Kathleen F.} and Taren, {Douglas L} and Cynthia Thomson and Bennett, {Robert M.} and Jones, {Kim D.}",
year = "2012",
language = "English (US)",
volume = "30",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "SUPPL.74",

}

TY - JOUR

T1 - The effect of dietary glutamate on fibromyalgia and irritable bowel symptoms

AU - Holton, Kathleen F.

AU - Taren, Douglas L

AU - Thomson, Cynthia

AU - Bennett, Robert M.

AU - Jones, Kim D.

PY - 2012

Y1 - 2012

N2 - Objective: To examine the effects of a challenge with monosodium glutamate (MSG) as compared to placebo on the symptoms of fibromyalgia (FM), in participants who initially experienced <30% remission of symptoms on an excitotoxin elimination diet. Methods: Fifty-seven FM patients who also had irritable bowel syndrome (IBS) were placed on a 4-week diet that excluded dietary additive excitotoxins including MSG and aspartame. Thirtyseven people completed the diet and 84% of those reported that <30% of their symptoms resolved, thus making them eligible to proceed to challenges. Subjects who improved on the diet were then randomised to a 2-week doubleblind placebo-controlled crossover challenge with MSG or placebo for 3 consecutive days each week. The primary outcome measure was total symptom score. Secondary outcome measures included visual analogue pain scales (VAS for FM and IBS), an IBS Quality of Life Questionnaire (IBS QOL) and the Fibromyalgia Impact QuestionnaireRevised (FIQR). Repeated measures ANOVA was used to analyse crossover challenge results. Results: The MSG challenge, as compared to placebo, resulted in a significant return of symptoms (total symptom score, p>0.02); a worsening of fibromyalgia severity as determined by the FIQR (p>0.03); decreased quality of life in regards to IBS symptoms (IBS QOL, p>0.05); and a non-significant trend toward worsening FM pain based on visual analogue scale (VAS, p>0.07). Conclusion: These findings suggest that dietary glutamate may be contributing to FM symptoms in some patients. Future research on the role of dietary excitotoxins in FM is warranted.

AB - Objective: To examine the effects of a challenge with monosodium glutamate (MSG) as compared to placebo on the symptoms of fibromyalgia (FM), in participants who initially experienced <30% remission of symptoms on an excitotoxin elimination diet. Methods: Fifty-seven FM patients who also had irritable bowel syndrome (IBS) were placed on a 4-week diet that excluded dietary additive excitotoxins including MSG and aspartame. Thirtyseven people completed the diet and 84% of those reported that <30% of their symptoms resolved, thus making them eligible to proceed to challenges. Subjects who improved on the diet were then randomised to a 2-week doubleblind placebo-controlled crossover challenge with MSG or placebo for 3 consecutive days each week. The primary outcome measure was total symptom score. Secondary outcome measures included visual analogue pain scales (VAS for FM and IBS), an IBS Quality of Life Questionnaire (IBS QOL) and the Fibromyalgia Impact QuestionnaireRevised (FIQR). Repeated measures ANOVA was used to analyse crossover challenge results. Results: The MSG challenge, as compared to placebo, resulted in a significant return of symptoms (total symptom score, p>0.02); a worsening of fibromyalgia severity as determined by the FIQR (p>0.03); decreased quality of life in regards to IBS symptoms (IBS QOL, p>0.05); and a non-significant trend toward worsening FM pain based on visual analogue scale (VAS, p>0.07). Conclusion: These findings suggest that dietary glutamate may be contributing to FM symptoms in some patients. Future research on the role of dietary excitotoxins in FM is warranted.

KW - Adverse effects

KW - Diet

KW - Fibromyalgia

KW - Glutamate

KW - Irritable bowel syndrome

UR - http://www.scopus.com/inward/record.url?scp=84860851850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860851850&partnerID=8YFLogxK

M3 - Article

C2 - 22766026

AN - SCOPUS:84860851850

VL - 30

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - SUPPL.74

ER -